Clinical Trials Logo

Clinical Trial Summary

Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05458752
Study type Observational
Source Central Hospital, Nancy, France
Contact
Status Completed
Phase
Start date April 1, 2020
Completion date July 1, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04851015 - Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia Phase 3
Completed NCT05707156 - Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
Recruiting NCT06173453 - Factors Associated With Survival in Patients Having Pneumocystis Jirovecii